Apollomics APLM
NASDAQ APLM
$23.57 -0.02 (-0.08%)
At close: Aug 20, 2026 · 4:00 PM EDT

Apollomics (APLM) Total Debt (2025)

Apollomics (APLM) posted quarterly Total Debt of $3.0 million for Q4 2025.

Apollomics (APLM) Total Debt (2025) Analysis & Trends

Apollomics (APLM) has reported Total Debt for 1 consecutive years, with $3.0 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Total Debt changed N/A year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $3.0 million (changed N/A YoY), while the FY2025 annual figure was $3.0 million, changed N/A from the prior year.
  • Total Debt steadied at $3.0 million in Q4 2025 per APLM's latest filing.
  • Across five years, Total Debt topped out at $3.0 million in Q4 2025 and bottomed at $3.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn -
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn 591.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 1.07 Bn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn -
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn 546.77 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn - 9.34 Bn
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn 770.36 Mn
10 Apollomics 34.08 Mn 30.81 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 3.02 Mn